<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199832</url>
  </required_header>
  <id_info>
    <org_study_id>20190920</org_study_id>
    <nct_id>NCT04199832</nct_id>
  </id_info>
  <brief_title>To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy</brief_title>
  <official_title>Nutritional Status and Complications in Patients Undergoing Chemoradiotherapy for Esophageal Squamous Cell Carcinomas: a Comparison of Nasogastric Tube, Percutaneous Endoscopic Gastrostomy Tube and Oral Supplement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study prospectively recruited esophageal squamous-cell carcinoma patients who received
      nasogastric tube (NG), gastrostomy feeding and oral intake to compare the changes in
      nutritional status and quality of life during chemoradiation therapy (CRT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Body Weight Change from baseline to the end of treatment</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>Body weight change from baseline to the end of treatment = body weight at the end of treatment - baseline body weight.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood biochemical examination</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>albumin,prealbumin,haemoglobin,et al, record the changes before and after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scored Patient-Generated Subjective Global Assessment (PG-SGA)</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>Nutritional status evaluation table. score: 0-1 A: well-nourished; score：2-8 B: moderately malnourished; score：≥9 C: severely malnourished.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ－C30</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>Quality of life evaluation form. QLQ-C30 results were linearly transformed to scores 0 to 100. Higher scores represent worse symptoms in the symptom scales and better function in functional scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-5 toxicity</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>Grade 3-5 adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 andthe criteria of the Radiation Therapy Oncology Group ，such as esophagitis、pneumonitis 、hematologic toxicity and infection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion rate of chemoradiotherapy</measure>
    <time_frame>up to 1 month after the treatment</time_frame>
    <description>The proportion of people who complete all treatment as required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>at least 2 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Chemoradiotherapy</condition>
  <condition>Enteral Nutrition</condition>
  <arm_group>
    <arm_group_label>Nasogastric tube</arm_group_label>
    <description>The patient had difficulty swallowing before chemoradiotherapy and placed a nasogastric tube.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gastrostomy feeding</arm_group_label>
    <description>Patients with dysphagia before chemoradiotherapy began to voluntarily choose gastrostomy feeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral intake</arm_group_label>
    <description>Patients with normal swallowing or not receiving tube feeding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary guidance</intervention_name>
    <description>Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.</description>
    <arm_group_label>Nasogastric tube</arm_group_label>
    <arm_group_label>Oral intake</arm_group_label>
    <arm_group_label>gastrostomy feeding</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with esophageal squamous cell carcinoma who received concurrent chemoradiotherapy
        voluntarily chose different nutritional treatment paths according to the degree of
        dysphagia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically or cytologically proven esophageal squamous cell carcinoma

          -  Karnofsky performance score(KPS) ≧70

          -  Concurrent chemoradiotherapy

          -  Hemoglobin≥90.0g/dL,white blood cell count（WBC）≥ 4000 cells/mm³,Platelet count≥100,000
             cells/mm³

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 times upper
             limit of normal,bilirubin normal

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  Patients have good compliance to treatment and follow-up of acceptance

          -  the functions of the heart, kidney, liver were basically normal, with no chemotherapy
             and radiotherapy contraindications

        Exclusion Criteria:

          -  Patients with severely bowel function impaired or can not tolerate enteral nutrition

          -  Patients with serious gastrointestinal obstruction, be unable to take food by mouth
             and can not / do not want to a feeding tube inserted

          -  Patients who have severe vomiting, gastrointestinal bleeding, intestinal obstruction

          -  Patients who have distant metastasis

          -  The primary tumor or lymph node already received surgical treatment efuse or incapable
             to sign the informed consent form of participating this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingsong Pang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Radiation Oncology,Tianjin Medical University cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Dong, Doctor</last_name>
    <phone>+862223341405</phone>
    <email>dong437241269@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Tianjin Medical University cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>QingSong Pang, M.D</last_name>
      <phone>+86-22-23340123-1311</phone>
      <email>dong437241269@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

